Afelimomab
Alternative Names: Anti-tumour necrosis factor Fab antibody; MAK 195F; SegardLatest Information Update: 05 Feb 2013
At a glance
- Originator Abbott GmbH & Co. KG
- Class Anti-TNF monoclonal antibodies
- Mechanism of Action Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Graft-versus-host disease; Sepsis; Septic shock
Most Recent Events
- 29 Apr 2005 A study has been added to the adverse events and Bacterial Infections therapeutic trials sections
- 28 Sep 2001 A study has been added to the adverse events, pharmacokinetics and Bacterial Infections therapeutic trials sections
- 13 Mar 2001 BASF's pharmaceutical business has been acquired by Abbott Laboratories